Quent Long Short Global Small Cap Fund LP Invests $483,000 in United Therapeutics Corporation $UTHR

Quent Long Short Global Small Cap Fund LP purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 992 shares of the biotechnology company’s stock, valued at approximately $483,000.

Other institutional investors also recently made changes to their positions in the company. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Wilmington Savings Fund Society FSB lifted its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Abich Financial Wealth Management LLC acquired a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $44,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 85 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 9,636 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,801,035.96. The trade was a 33.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $576.82, for a total transaction of $4,787,606.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at $26,056,113.04. This represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 443,205 shares of company stock valued at $236,868,116 over the last quarter. Company insiders own 10.30% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $567.16 on Friday. The company’s 50 day simple moving average is $536.51 and its 200 day simple moving average is $494.03. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $607.89. The company has a market capitalization of $24.86 billion, a P/E ratio of 20.33, a PEG ratio of 1.63 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same period in the previous year, the firm earned $6.19 EPS. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of research analyst reports. Morgan Stanley upped their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. TD Cowen boosted their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 31st. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $601.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.